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The preliminary results of ovarian transplantation in clinical practice are encouraging. However, the follicular
depletion caused by ischemic injury is a main concern and is directly related to short-term graft survival. Cell therapy
with adipose tissue-derived stem cells (ASCs) could be an alternative to induce early angiogenesis in the graft. This
study aimed to evaluate ASCs therapy in rat cryopreserved ovarian grafts. A single dose of rat ASC (rASCs) or vehicle
was injected into the bilateral cryopreserved ovaries of twelve adult female rats immediately after an autologous
transplant. Daily vaginal smears were performed for estrous cycle evaluation until euthanasia on postoperative day
30. Follicle viability, graft morphology and apoptosis were assessed. No differences were found with respect to
estrous cycle resumption and follicle viability (P > 0.05). However, compared with the vehicle-treated grafts, the
morphology of the ASCs-treated grafts was impaired, with diffuse atrophy and increased apoptosis (P < 0.05). ASCs
direct injected in the stroma of rat cryopreserved ovarian grafts impaired its morphology although may not interfere
with the functional resumption on short-term. Further investigations are necessary to evaluated whether it could
compromise their viability in the long-term.Findings
Background
Despite the reestablishment of the endocrine function
after ovary transplantation, follicular depletion caused by
an ischemic lesion is a main concern and is directly re-
lated to short-term graft survival [1-5]. The challenges
to be met in the next few years should include a focus
on the improvement of cryopreservation techniques and
on host bed conditions [3]. Cell therapy with adipose
tissue-derived stem cells (ASCs) may be a viable and ad-
vantageous alternative to current approaches.
The therapeutic potential of ASCs has been demon-
strated in a number of preclinical models. When there is
a lesion, ASCs lessen tissue damage, inhibit fibrotic re-
modeling and apoptosis, promote angiogenesis, stimu-
late endogenous stem cell recruitment and proliferation,
and reduce the immune response [6]. Studies with* Correspondence: lucianadamous@gmail.com
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unless otherwise stated.animal models are necessary to understand the induc-
tion of angiogenesis in an ischemic environment and to
ensure that treatment with such cells is safe [7].
Improvements in rat ovarian function have been achieved
by the direct injection of ASCs into ovaries damaged by
chemotherapy drugs [8,9]. However, few data are cur-
rently available on the therapeutic potential of ASCs in
ovarian transplantation. An initial assessment was car-
ried out to evaluate the feasibility and safety of this line
of inquiry, in which rat ASCs transgenic for the green
fluorescent protein (GFP) were injected into fresh rat
grafts. ASCs were found to remain viable in ovarian tis-
sue without inducing morphological changes or func-
tional damage; some even assumed an endothelial
phenotype and promoted early resumption of the es-
trous cycle and an increase in angiogenesis (LLD, un-
published observations). Nevertheless, there is not
enough current knowledge of ASCs actions in cryopre-
served grafts. For this reason, this study aimed to deter-
mine whether ASCs therapy could improve the viability
of cryopreserved ovarian grafts, allowing for transla-
tional results.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The study was carried out at the Laboratory of Structural
and Molecular Gynecology (LIM-58), Gynecology Discip-
line, Department of Obstetrics and Gynecology, Hospital
das Clínicas da Faculdade de Medicina da Universidade de
Sao Paulo (FMUSP), in cooperation with the Laboratory
of Genetics and Molecular Cardiology/Heart Institute/
FMUSP. The experimental procedures followed the insti-
tutional guidelines for the care and use of laboratory an-
imals and were approved by the Institutional Ethics
Committee/FMUSP, protocol 190/10, approved on 14
April 2011. This study was initiated in July 2013 and ter-
minated in January 2014.
The study sample consisted of 12 twelve-week-old
adult female Wistar (Rattus norvegicus albinus) rats. The
animals had access to a breed-specific food formula and
water ad libitum throughout the experiment and were
kept under adequate sanitary, lighting (12 hour), and
temperature conditions in the animal laboratory. Before
the experiment, vaginal smears were obtained daily.
Only those animals showing at least two consecutive
normal four-day vaginal estrous cycles were included
in the experiment. The ovarian transplant was performed
during the diestrous phase.
Rat ASCs (rASCs) obtained from the inguinal region
of Wistar rats or vehicle were injected into bilateral
ovarian grafts of 12 Wistar rats. An ovarian graft is the
whole frozen-thawed ovary grafted into the retroperito-
neum, one on each side of the psoas muscle, without
vascular anastomosis.
ASCs isolation and ex vivo expansion
Inguinal subcutaneous adipose tissue was collected under
sterile conditions from ten-week-old male Wistar rats and
was rinsed with phosphate-buffered saline (PBS). ASCs
were isolated, characterized, and maintained in culture as
previously described [10]. Details are available in Additional
file 1 (ASCs isolation and ex vivo expansion).
The morphological and replicative characteristics and
the immunophenotypes (CD90+, CD29+, CD44+, CD73+,
CD31−, CD45−) of the ASCs have been previously deter-
mined in our laboratory [11]. Despite the fact that the
characterization had been done extensively in mice
adipose-derived stem cells (mASC), our group conducted
some immunophenotyping assays with rASCs. Accord-
ingly, the percentage of CD90 and CD29 positive cells, the
main markers of a variety of adult stem cells, was found to
be around 90% (92, 65% and 98, 89%, respectively) in
rASC at the third culture passage (JSN et al., unpublished
observations).
Operative procedures
The rats were anesthetized intraperitoneally with xyla-
zine and ketamine. After bilateral oophorectomy, thefresh ovaries were immediately frozen in a slow-cooling
freezer (CL-8800, Cryogenesis software, Freezer Control)
as previously described [12]. Details are available in
Additional file 2 (ovarian cryopreservation). A second
laparotomy was performed 24 hours after ovarian cryo-
preservation. Each animal received a pair of autologous
ovary transplants. With a simple stitch of 4–0 nylon
suture, intact whole ovaries were implanted in the ret-
roperitoneum, one on each side of the psoas muscle, in
proximity to the aorta and vena cava, without vascular
anastomosis.
At this point, the rats were distributed into two experi-
mental groups of six animals each, according to treatment,
as follows: vehicle (low glucose DMEM) or ASCs at a
concentration of 5 × 104 cells in 25 μl of vehicle/ovary.
The technical standardization of ASCs injection was per-
formed according to a pilot project conducted in the
intact ovary (topic) in which ASCs obtained from rats
transgenic for GFP (ASC-GFP+) were injected. In this, we
tested different vehicle volumes for cell delivery (ranging
from 2 to 50 μl) with the aid of a surgical microscope. The
standard dose of 25 μl was the lowest in which no leakage
was visually observed following the injection, without
changes in ovary morphology and ASC-GFP+ were
easily identified and quantified in ovarian stroma (Data
not shown).
The treatment was injected into both ovarian grafts
with only one shot into the center of the ovarian paren-
chyma. No leakage was visually observed after injection.
The procedures were carried out with the aid of a surgi-
cal microscope (16x).
Beginning on postoperative (PO) day 4, vaginal smears
were obtained from each rat between 8:00 a.m. and
10:00 a.m. daily until euthanasia, which was performed
between day 30 and day 35, always when the rats were
in diestrous phase. The animals underwent a third surgi-
cal procedure and the grafts were subsequently removed
whole.
One ovarian graft was immediately fixed in 4% para-
formaldehyde for at least 24 hours. After fixation, the
ovaries were dehydrated, paraffin-embedded, serially sec-
tioned at 5 μm, and mounted on glass microscope slides.
Routine hematoxylin and eosin (H & E) staining was
performed for histologic examination via light micros-
copy. The other ovarian graft was prepared for the fol-
licular viability assay. After this procedure, the animals
were euthanized with a lethal dose of the previously used
anesthetics.
Morphological analyses
Morphological evaluation was achieved through descrip-
tive analyses of the grafts. Assessment of follicular qual-
ity was based on cell density, the presence or absence of
pyknotic bodies, and the integrity of the basement
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follicles were classified as normal or degenerated; only the
former were characterized and quantified. Viable follicles
were classified as previously described [13].
Follicular viability assay
Using a modified protocol [14], the analysis of the follicle
viability was carried out as detailed in Additional file 3
(follicular viability assay). A three-fold manual count of
each well was performed under an inverted microscope
(EVOS® XL Core Cell Imaging System, AMG) at 200×
magnification to allow for individualization of the white
(viable) and blue (atretic) follicles in absolute numbers as
well as in percentages of viable follicles.
Apoptosis assay
Sections containing ovarian stroma were immunostained
to measure apoptosis via cleaved-caspase-3 expression
(SANT-SC-1226, 1:100, Santa Cruz Biotechnology, Inc. Santa
Cruz, CA, EUA) and the terminal deoxynucleotidyl transfer-
ase (TdT)–mediated dUTP nickend labeling (TUNEL) assay
using a commercially available kit (In Situ Cell Death Detec-
tion Kit, Fluorescein, Roche, Berlin, Germany, 11684795910)
following the manufacturer’s instructions. Red-brown color-
ing of the cytoplasm/nucleus of the granulosa cells was con-
sidered positive staining (any other coloring was considered
negative staining). For the negative controls, the primary
antibody was omitted to avoid bias.
Images of the sections were obtained using an image
acquisition software system (Leica DM2500); measure-
ments were made using the Leica QWin V3 software.
Red-brown coloring of the cytoplasm/nucleus of the
stroma cells was specified as positive staining (anything
else as negative staining). A positive cell staining assess-
ment was performed in four different fields per animal
at 200x magnification and the results are expressed as a
percentage of the positive area (arbitrary unity/mm2).
Two independent investigators blinded to the experi-
mental treatments performed all measurements.
Statistical analysis
The results were expressed as the mean ± standard devi-
ation of the mean. The unpaired t-test was utilized to
compare groups (vehicle and ASCs). All statistical analyses
were performed using Graphpad Prism 4.0 (Graphpad
Software Inc, CA, San Diego, USA). P values less than
0.05 were considered significant.
Results
Estrous cycle resumption after transplantation
All animals resumed cycling after transplantation, and
the PO day of estrous phase identification was similar
for all treatment groups (vehicle: 16.66 ± 2 versus ASCs:
18.66 ± 5.77, P >0.05).Morphology and follicular viability of the grafts 30 days
after transplantation
In the vehicle-treated animals, ovarian follicles were ob-
served at various stages of maturation, from primordial
follicles to preovulatory follicles, occasionally with lu-
teinization on the wall. Corpora lutea and occasional
corpora albicans were detected. In the ASCs-treated ani-
mals, the ovarian grafts displayed diffuse atrophy and
corpora albicans. The vascular network exhibited thick-
ening and hyalinization of the blood vessel walls associ-
ated with the obliteration of the lumen. The presence of
gigantocellular reactions of the foreign body type to the
suture was also observed. The percentage of viable ovar-
ian follicles by trypan blue was similar between groups
(vehicle: 85.2 ± 6.8 versus ASCs: 74.5 ± 10.3, P >0.05)
(Figure 1, Table 1).
Apoptosis assay
The ASCs treatment boosted apoptosis as measured
both by the cleaved-caspase-3 (vehicle: 2.52 ± 0.73 versus
ASCs: 4.11 ± 1.07, P <0.05) and the TUNEL (vehicle:
0.17 ± 0.18 versus ASCs: 0.52 ± 0.46, P <0.05) methods
(Figure 1).
Discussion
The ASCs-treated cryopreserved ovarian grafts main-
tained the percentage of viable ovarian follicles and did
not alter the functional resumption of the graft, as evi-
denced by the estrous phase resumption in the vaginal
smears. The morphology of the ASCs-treated grafts,
however, was more impaired, as indicated by more fibro-
sis, a predominance of corpora albicans, and increased
apoptosis. In the long-term, this therapy might nega-
tively affect the viability of cryopreserved ovarian tissue.
The direct injection of ASCs may have overstimulated
the intrinsic inflammatory response in an environment
already under adverse hypoxic conditions. Our experi-
mental model has some limitations: 1) clinical applica-
tion is not possible due to the rat ovary being different
from the human one; and 2) further long-term study
with fresh grafts is necessary to confirm our results.
Another relevant point is the type of lesion induced in
the ovary. In ovaries damaged by chemotherapy drugs,
the ASCs treatment promoted functional recovery and
mitigated the lesions [8,9]. Further, fresh ovarian grafts
showed early functional resumption with no changes in
apoptosis (LLD, unpublished observations). In the present
model, ovaries cryopreserved by slow freezing are bio-
logically different from fresh tissue, which has only under-
gone oophorectomy, or from tissue severely impaired by
chemotherapy drugs. Cryoinjury has been exhaustively
investigated in human and animal tissues because of the
attainable translational results. The current consensus is
that ischemia prior to graft revascularization rather than
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Figure 1 Photomicrography of cryopreserved ovarian grafts treated with vehicle or ASC 30 days after an autologous avascular transplant. The
morphology of the ASCs-treated grafts shows increased fibrosis and more corpora albicans, but the follicle viability was maintained, as evidenced by
trypan blue (A) (P >0.05). Immunohistochemistry for apoptosis was performed on the ovarian stroma, and dark brown-stained cells are considered
positive. Results are expressed as a percentage of the positive area (arbitrary unity/mm2). Apoptosis increased in both analyses (cleaved-caspase-3 and
TUNEL) of the ASC-treated grafts (B and C) (P <0.05). H & E 100x. Immunohistochemistry analysis 200x. ASCs, adipose tissue-derived stem cells;
CL, corpora lutea; CA, corpora albicans; F, fibrosis. * P <0.05, unpaired t-test.
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follicular loss [2,4]. It cannot be stated, however, that
cryopreservation is completely inert concerning the
ovarian tissue [13,15-18].
In clinical practice, long-term follow-up is still scarce.
The slow-freezing protocol has been used in every case
of a baby born from ovary transplantation to date [3]. A
recent literature review showed that the pattern of func-
tional resumption was the same for fresh and cryopre-
served grafts. However, the survival of the cryopreservedTable 1 Ovarian follicles after isolation and trypan blue stain
Rats
Vehicle
Number unstained Number blue Viable follicles (%
R1 60 12 83.33
R2 83 20 80.58
R3 67 8 89.33
R4 46 3 93.87
R5 49 6 89.09
R6 54 18 75
Mean 59.8 ± 12.4 11.1 ± 6.1 85.2 ± 6.2
Data are shown as mean number (±Standard Deviation), P>0.05, paired t-test.grafts was two-thirds shorter than that of the fresh grafts
[19], a fact that may be due to the intrinsic problems of
slow freezing. Thus, the development of improved ovar-
ian tissue freezing techniques for transplantation is a
current priority to increase the success rates of the tech-
nique [3].
As ASCs were observed to remain viable in ovarian
tissue for 30 days after a single injection into the center
of the parenchyma (LLD, unpublished observations), we
believe this therapy should be further investigated in aing, according to treatment
ASCs
) Number unstained Number blue Viable follicles (%)
45 12 78.94
73 11 86.9
35 7 83.33
42 28 60
52 30 72.22
33 50 66
46.6 ± 13.3 23 ± 14.8 74.5 ± 9.4
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the increase in apoptosis found in this study. We assume
that the direct injection of ASCs into the cryopreserved
ovarian tissue with attendant exacerbation of the local
inflammatory response may have been an overly aggres-
sive treatment. Therefore, it is necessary to develop new
strategies for delivering ASCs.
ASCs are usually administered by systemic injection
(intravenous or intra-arterial) or local injection into
damaged tissues. These administration methods may
affect cell viability and the dose actually delivered. Coun-
terpressure and tissue density should be taken into ac-
count to control for the cell dose and to maintain the
structural integrity of the cells [20]. Another option is to
deliver the ASCs through an acellular matrix. This strat-
egy has several advantages over a direct injection, such
as allowing prolonged contact with the target tissue,
prompting cell retention, and furthering the gradual and
continuous release of proangiogenic factors [21]. This
being the case, the next technical challenges that must
be overcome in ASCs treatment are how to reach the
target tissue with precision and how to optimize ASCs
action to keep the cells viable in large enough quantities
and for a long enough time to trigger the expected
therapeutic action.
Conclusions
ASCs directly injected in the stroma of rat cryopreserved
ovarian grafts impaired its morphology although they
may not have interfered with the resumption of its func-
tion in the short-term. Further investigations are necessary
to evaluate whether it could compromise their viability in
the long-term.
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